Skip to main content
Top
Published in: Lung 6/2014

01-12-2014

Using Cluster Analysis to Identify Phenotypes and Validation of Mortality in Men with COPD

Authors: Chiung-Zuei Chen, Liang-Yi Wang, Chih-Ying Ou, Cheng-Hung Lee, Chien-Chung Lin, Tzuen-Ren Hsiue

Published in: Lung | Issue 6/2014

Login to get access

Abstract

Purpose

Cluster analysis has been proposed to examine phenotypic heterogeneity in chronic obstructive pulmonary disease (COPD). The aim of this study was to use cluster analysis to define COPD phenotypes and validate them by assessing their relationship with mortality.

Methods

Male subjects with COPD were recruited to identify and validate COPD phenotypes. Seven variables were assessed for their relevance to COPD, age, FEV1 % predicted, BMI, history of severe exacerbations, mMRC, SpO2, and Charlson index. COPD groups were identified by cluster analysis and validated prospectively against mortality during a 4-year follow-up.

Results

Analysis of 332 COPD subjects identified five clusters from cluster A to cluster E. Assessment of the predictive validity of these clusters of COPD showed that cluster E patients had higher all cause mortality (HR 18.3, p < 0.0001), and respiratory cause mortality (HR 21.5, p < 0.0001) than those in the other four groups. Cluster E patients also had higher all cause mortality (HR 14.3, p = 0.0002) and respiratory cause mortality (HR 10.1, p = 0.0013) than patients in cluster D alone.

Conclusion

COPD patient with severe airflow limitation, many symptoms, and a history of frequent severe exacerbations was a novel and distinct clinical phenotype predicting mortality in men with COPD.
Literature
1.
go back to reference Garcia-Aymerich J, Gómez FP, Benet M et al (2011) Identification and prospective validation of clinically relevant chronic obstructive pulmonary disease (COPD) subtypes. Thorax 66:430–437CrossRefPubMed Garcia-Aymerich J, Gómez FP, Benet M et al (2011) Identification and prospective validation of clinically relevant chronic obstructive pulmonary disease (COPD) subtypes. Thorax 66:430–437CrossRefPubMed
2.
go back to reference Burgel PR, Paillasseur JL, Caillaud D et al (2010) Clinical COPD phenotypes: a novel approach using principal component and cluster analyses. Eur Respir J 36:531–539CrossRefPubMed Burgel PR, Paillasseur JL, Caillaud D et al (2010) Clinical COPD phenotypes: a novel approach using principal component and cluster analyses. Eur Respir J 36:531–539CrossRefPubMed
3.
go back to reference Burgel PR, Roche N, Paillasseur JL et al (2012) Clinical COPD phenotypes identified by cluster analyses: validation with mortality. Eur Respir J 40:495–512CrossRefPubMed Burgel PR, Roche N, Paillasseur JL et al (2012) Clinical COPD phenotypes identified by cluster analyses: validation with mortality. Eur Respir J 40:495–512CrossRefPubMed
4.
go back to reference Burgel PR, Paillasseur JL, Peene B et al (2012) Two distinct chronic obstructive pulmonary disease (COPD) phenotypes are associated with high risk of mortality. PLoS One 7(12):e51048PubMedCentralCrossRefPubMed Burgel PR, Paillasseur JL, Peene B et al (2012) Two distinct chronic obstructive pulmonary disease (COPD) phenotypes are associated with high risk of mortality. PLoS One 7(12):e51048PubMedCentralCrossRefPubMed
5.
go back to reference Weatherall M, Travers J, Shirtcliffe PM et al (2009) Distinct clinical phenotypes of airways disease defined by cluster analysis. Eur Respir J 34:812–818CrossRefPubMed Weatherall M, Travers J, Shirtcliffe PM et al (2009) Distinct clinical phenotypes of airways disease defined by cluster analysis. Eur Respir J 34:812–818CrossRefPubMed
7.
go back to reference Cho MH, Washko GR, Hoffmann TJ et al (2010) Cluster analysis in severe emphysema subjects using phenotype and genotype data: an exploratory investigation. Respir Res 11:30PubMedCentralCrossRefPubMed Cho MH, Washko GR, Hoffmann TJ et al (2010) Cluster analysis in severe emphysema subjects using phenotype and genotype data: an exploratory investigation. Respir Res 11:30PubMedCentralCrossRefPubMed
8.
go back to reference Han MK, Agusti A, Calverley PM et al (2010) Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med 182:598–604CrossRefPubMed Han MK, Agusti A, Calverley PM et al (2010) Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med 182:598–604CrossRefPubMed
9.
go back to reference Wardlaw AJ, Silverman M, Siva R et al (2005) Multi-dimensional phenotyping: towards a new taxonomy for airway disease. Clin Exp Allergy 35:1254–1262CrossRefPubMed Wardlaw AJ, Silverman M, Siva R et al (2005) Multi-dimensional phenotyping: towards a new taxonomy for airway disease. Clin Exp Allergy 35:1254–1262CrossRefPubMed
10.
go back to reference Seemugal TAR, Donaldson GC, Paul EA et al (1998) Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 157:1418–1422CrossRef Seemugal TAR, Donaldson GC, Paul EA et al (1998) Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 157:1418–1422CrossRef
11.
12.
go back to reference Wedzicha JA, Seemungal TAR (2007) COPD exacerbations: defining their cause and prevention. Lancet 370:786–796CrossRefPubMed Wedzicha JA, Seemungal TAR (2007) COPD exacerbations: defining their cause and prevention. Lancet 370:786–796CrossRefPubMed
13.
go back to reference Hurst JR, Vestbo J, Anzueto A et al (2010) Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 363:1128–1138CrossRefPubMed Hurst JR, Vestbo J, Anzueto A et al (2010) Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 363:1128–1138CrossRefPubMed
14.
go back to reference Soler-Cataluña JJ, Martinez-Garcia MA, Sánchez PR et al (2005) Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 60:925–931PubMedCentralCrossRefPubMed Soler-Cataluña JJ, Martinez-Garcia MA, Sánchez PR et al (2005) Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 60:925–931PubMedCentralCrossRefPubMed
15.
go back to reference Garcia-Aymerich J, Farrero E, Félez MA et al (2003) Risk factors of readmission to hospital for a COPD exacerbation: a prospective study. Thorax 58:100–105PubMedCentralCrossRefPubMed Garcia-Aymerich J, Farrero E, Félez MA et al (2003) Risk factors of readmission to hospital for a COPD exacerbation: a prospective study. Thorax 58:100–105PubMedCentralCrossRefPubMed
16.
go back to reference Celli BR, Jones P, Vestbo J et al (2008) The multidimensional BOD: association with mortality in the TORCH trial. Eur Respir J 32(Suppl. 52):42s Celli BR, Jones P, Vestbo J et al (2008) The multidimensional BOD: association with mortality in the TORCH trial. Eur Respir J 32(Suppl. 52):42s
17.
go back to reference Puhan MA, Garcia-Aymerich J, Frey M et al (2009) Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index. Lancet 374:704–711CrossRefPubMed Puhan MA, Garcia-Aymerich J, Frey M et al (2009) Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index. Lancet 374:704–711CrossRefPubMed
18.
go back to reference Sin DD, Anthonisen NR, Soriano JB, Agusti AG (2006) Mortality in COPD: role of comorbidities. Eur Respir J 28:1245–1257CrossRefPubMed Sin DD, Anthonisen NR, Soriano JB, Agusti AG (2006) Mortality in COPD: role of comorbidities. Eur Respir J 28:1245–1257CrossRefPubMed
19.
go back to reference Incalzi RA, Fuso L, DeRosa M et al (1997) Co-morbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease. Eur Respir J 10:2794–2800CrossRef Incalzi RA, Fuso L, DeRosa M et al (1997) Co-morbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease. Eur Respir J 10:2794–2800CrossRef
20.
go back to reference Nocturnal Oxygen Therapy Trial Group (1980) Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive pulmonary disease: a clinical trial. Ann Intern Med 93:391–398CrossRef Nocturnal Oxygen Therapy Trial Group (1980) Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive pulmonary disease: a clinical trial. Ann Intern Med 93:391–398CrossRef
21.
go back to reference Global Initiative for Chronic Obstructive Lung Disease (GOLD) (2006) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease, 2006 updated. National Heart, Lung and Blood Institute/World Health Organization, Bethesda Global Initiative for Chronic Obstructive Lung Disease (GOLD) (2006) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease, 2006 updated. National Heart, Lung and Blood Institute/World Health Organization, Bethesda
22.
go back to reference Blonshine S, Mottram CD, Wanger J (2005) Pulmonary Function Laboratory Management and Procedure Manual, 2nd edn. American Thoracic Society, New York Blonshine S, Mottram CD, Wanger J (2005) Pulmonary Function Laboratory Management and Procedure Manual, 2nd edn. American Thoracic Society, New York
23.
go back to reference Chen CZ, Ou CY, Wang WL et al (2012) Using post-bronchodilator FEV1 is better than pre-bronchodilator FEV1 in evaluation of COPD severity. COPD 9:276–280CrossRefPubMed Chen CZ, Ou CY, Wang WL et al (2012) Using post-bronchodilator FEV1 is better than pre-bronchodilator FEV1 in evaluation of COPD severity. COPD 9:276–280CrossRefPubMed
24.
go back to reference Hnizdo E, Glindmeyer HW, Petsonk EL et al (2006) Case definitions for chronic obstructive pulmonary disease. COPD 3:95–100CrossRefPubMed Hnizdo E, Glindmeyer HW, Petsonk EL et al (2006) Case definitions for chronic obstructive pulmonary disease. COPD 3:95–100CrossRefPubMed
25.
go back to reference Hardie JA, Buist AS, Vollmer WM et al (2002) Risk of over-diagnosis of COPD in asymptomatic elderly never-smokers. Eur Respir J 20:1117–1122CrossRefPubMed Hardie JA, Buist AS, Vollmer WM et al (2002) Risk of over-diagnosis of COPD in asymptomatic elderly never-smokers. Eur Respir J 20:1117–1122CrossRefPubMed
26.
go back to reference Curtis JR (2008) Palliative and end-of-life care for patients with severe COPD. Eur Respir J 32:796–803CrossRefPubMed Curtis JR (2008) Palliative and end-of-life care for patients with severe COPD. Eur Respir J 32:796–803CrossRefPubMed
27.
go back to reference Brown DW, Croft JB, Greenlund KJ et al (2008) Deaths from chronic obstructive pulmonary disease: united States, 2000–2005. MMWR Surveill Summ 57:1229–1232 Brown DW, Croft JB, Greenlund KJ et al (2008) Deaths from chronic obstructive pulmonary disease: united States, 2000–2005. MMWR Surveill Summ 57:1229–1232
28.
go back to reference Blanchette CM, Berry SR, Lane SJ (2011) Advances in chronic obstructive pulmonary disease among older adults. Curr Opin Pulm Med 17:84–89CrossRefPubMed Blanchette CM, Berry SR, Lane SJ (2011) Advances in chronic obstructive pulmonary disease among older adults. Curr Opin Pulm Med 17:84–89CrossRefPubMed
30.
go back to reference Almagro P, Calbo E, Ochoa de Echagüen A et al (2002) Mortality after hospitalization for COPD. Chest 121:1441–1448CrossRefPubMed Almagro P, Calbo E, Ochoa de Echagüen A et al (2002) Mortality after hospitalization for COPD. Chest 121:1441–1448CrossRefPubMed
31.
go back to reference Groenewegen KH, Scholas AMWJ, Wouters E (2003) Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. Chest 124:459–1467CrossRefPubMed Groenewegen KH, Scholas AMWJ, Wouters E (2003) Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. Chest 124:459–1467CrossRefPubMed
32.
go back to reference Johannessen A, Skorge TD, Bottai M et al (2013) Mortality by level of emphysema and airway wall thickness. Am J Respir Crit Care Med 187:602–608CrossRefPubMed Johannessen A, Skorge TD, Bottai M et al (2013) Mortality by level of emphysema and airway wall thickness. Am J Respir Crit Care Med 187:602–608CrossRefPubMed
33.
go back to reference Martinez FJ, Foster G, Curtis JL et al (2006) Predictors of mortality in patients with emphysema and severe airflow obstruction. Am J Respir Crit Care Med 173:1326–1334PubMedCentralCrossRefPubMed Martinez FJ, Foster G, Curtis JL et al (2006) Predictors of mortality in patients with emphysema and severe airflow obstruction. Am J Respir Crit Care Med 173:1326–1334PubMedCentralCrossRefPubMed
34.
go back to reference O’Donnell DE, Laveneziana P (2006) Physiology and consequences of lung hyperinflation in COPD. Eur Respir Rev 15(100):61–67CrossRef O’Donnell DE, Laveneziana P (2006) Physiology and consequences of lung hyperinflation in COPD. Eur Respir Rev 15(100):61–67CrossRef
35.
go back to reference Thomas M, Decramer M, O’Donnell DE (2013) No room to breathe: the importance of lung hyperinflation in COPD. Prim Care Respir J 22(1):101–111CrossRefPubMed Thomas M, Decramer M, O’Donnell DE (2013) No room to breathe: the importance of lung hyperinflation in COPD. Prim Care Respir J 22(1):101–111CrossRefPubMed
36.
go back to reference Casanova C, Cote C, de Torres JP et al (2005) Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 171:591–597CrossRefPubMed Casanova C, Cote C, de Torres JP et al (2005) Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 171:591–597CrossRefPubMed
37.
go back to reference Regional COPD Working Group (2003) COPD prevalence in 12 Asia-Pacific countries and regions: projections based on the COPD prevalence estimation model. Respirology 8:192–198CrossRef Regional COPD Working Group (2003) COPD prevalence in 12 Asia-Pacific countries and regions: projections based on the COPD prevalence estimation model. Respirology 8:192–198CrossRef
39.
go back to reference Han MK, Martinez CH, Curtis JL et al (2012) Gender differences in AECOPD in the NIH-sponsored Azithronycin in COPD trial. Am J Respire Crit Care Med 185:A4448 Han MK, Martinez CH, Curtis JL et al (2012) Gender differences in AECOPD in the NIH-sponsored Azithronycin in COPD trial. Am J Respire Crit Care Med 185:A4448
Metadata
Title
Using Cluster Analysis to Identify Phenotypes and Validation of Mortality in Men with COPD
Authors
Chiung-Zuei Chen
Liang-Yi Wang
Chih-Ying Ou
Cheng-Hung Lee
Chien-Chung Lin
Tzuen-Ren Hsiue
Publication date
01-12-2014
Publisher
Springer US
Published in
Lung / Issue 6/2014
Print ISSN: 0341-2040
Electronic ISSN: 1432-1750
DOI
https://doi.org/10.1007/s00408-014-9646-x

Other articles of this Issue 6/2014

Lung 6/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.